ATE364697T1 - Edg8-rezeptor, dessen herstellung und verwendung - Google Patents

Edg8-rezeptor, dessen herstellung und verwendung

Info

Publication number
ATE364697T1
ATE364697T1 AT01949287T AT01949287T ATE364697T1 AT E364697 T1 ATE364697 T1 AT E364697T1 AT 01949287 T AT01949287 T AT 01949287T AT 01949287 T AT01949287 T AT 01949287T AT E364697 T1 ATE364697 T1 AT E364697T1
Authority
AT
Austria
Prior art keywords
production
receptor
polynucleotides
edg8
edg8 receptor
Prior art date
Application number
AT01949287T
Other languages
English (en)
Inventor
Evi Kostenis
Johann Gassenhuber
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00108858A external-priority patent/EP1149907A1/de
Priority claimed from EP00116589A external-priority patent/EP1178110A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE364697T1 publication Critical patent/ATE364697T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
AT01949287T 2000-04-26 2001-04-14 Edg8-rezeptor, dessen herstellung und verwendung ATE364697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108858A EP1149907A1 (de) 2000-04-26 2000-04-26 EDG8 Rezeptor, dessen Herstellung und Verwendung
EP00116589A EP1178110A1 (de) 2000-08-01 2000-08-01 EDG8 Rezeptor für Sphingosine 1-Phosphate , dessen Herstellung und Anwendung

Publications (1)

Publication Number Publication Date
ATE364697T1 true ATE364697T1 (de) 2007-07-15

Family

ID=26070860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01949287T ATE364697T1 (de) 2000-04-26 2001-04-14 Edg8-rezeptor, dessen herstellung und verwendung

Country Status (14)

Country Link
US (2) US20020099191A1 (de)
EP (1) EP1278850B1 (de)
JP (1) JP5139617B2 (de)
KR (1) KR100790329B1 (de)
AT (1) ATE364697T1 (de)
AU (2) AU2001270489B2 (de)
BR (1) BR0110248A (de)
CA (1) CA2406725C (de)
DE (1) DE60128906T2 (de)
IL (2) IL152378A0 (de)
MX (1) MXPA02010241A (de)
NO (1) NO331197B1 (de)
NZ (1) NZ522215A (de)
WO (1) WO2001081573A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
EP1448583A4 (de) * 2001-07-20 2006-02-08 Aventis Pharma Inc Gave8, ein neuer g-protein-gekoppelter rezeptor
AU2003301991A1 (en) * 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
WO2006014808A1 (en) * 2004-07-27 2006-02-09 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 5
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
AU5575299A (en) * 1998-08-19 2000-03-14 Millennium Pharmaceuticals, Inc. 14274 receptor, a g-protein coupled receptor related to the edg receptor family
WO2001004139A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
GB9923890D0 (en) * 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide

Also Published As

Publication number Publication date
WO2001081573A1 (en) 2001-11-01
US20030219874A1 (en) 2003-11-27
NO20025152L (no) 2002-12-13
CA2406725A1 (en) 2001-11-01
US7141383B2 (en) 2006-11-28
DE60128906T2 (de) 2008-02-07
NO331197B1 (no) 2011-10-31
BR0110248A (pt) 2003-01-07
NZ522215A (en) 2004-05-28
EP1278850B1 (de) 2007-06-13
EP1278850A1 (de) 2003-01-29
AU7048901A (en) 2001-11-07
AU2001270489B2 (en) 2007-03-15
IL152378A (en) 2010-12-30
KR100790329B1 (ko) 2008-01-02
JP5139617B2 (ja) 2013-02-06
US20020099191A1 (en) 2002-07-25
CA2406725C (en) 2013-01-15
DE60128906D1 (de) 2007-07-26
JP2003530882A (ja) 2003-10-21
MXPA02010241A (es) 2004-09-06
KR20020097234A (ko) 2002-12-31
IL152378A0 (en) 2003-05-29
NO20025152D0 (no) 2002-10-25

Similar Documents

Publication Publication Date Title
BG108495A (en) 5-ht receptor ligands and uses thereof
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
DE60140214D1 (de) Schraube zur befestigung der wirbelsäule
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MXPA03002971A (es) Receptores de hematopoyetina hpr1 y hpr2.
ATE363531T1 (de) Claudin polypeptide
ATE364697T1 (de) Edg8-rezeptor, dessen herstellung und verwendung
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
SE9801455D0 (sv) New receptor
DE602004023105D1 (de) HERSTELLUNG VON 4,5-DIALKYL-3-ACYLPYRROL-2-CARBONS ANSCHLIEßENDE ACYLIERUNG
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
WO2002002630A3 (en) Hcn polypeptides and polynucleotides and their use in therapy
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
TNSN06272A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
WO2005046602A3 (en) Vegf receptor antagonists
WO2003074656A3 (en) Rank-ligand-induced sodium/proton antiporter polypeptides
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
AU2003234717A8 (en) Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021
SE0001631D0 (sv) New use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties